All articles tagged with #tar 200
A new implant called TAR-200 has shown promising results in a phase 2 trial, eliminating tumors in 82% of high-risk bladder cancer patients resistant to previous treatments, with most tumors disappearing within three months and many patients remaining cancer-free after a year, offering a potentially safer and more effective alternative to traditional therapies.
A new bladder cancer treatment using the TAR-200 device, which delivers chemotherapy directly into the bladder, has shown promising results with 82% of patients experiencing cancer disappearance after three months, and nearly half remaining cancer-free after a year, representing a significant breakthrough in treatment options.
A new pretzel-shaped implant called TAR-200, containing chemotherapy drug gemcitabine, has shown promising results in eradicating bladder cancer in over 80% of patients, especially those with carcinoma in situ, by releasing the drug steadily over three weeks. The device, which is less invasive than surgery, has demonstrated higher response rates than existing treatments and is currently under FDA review, potentially revolutionizing bladder cancer therapy.
A new slow-release drug system called TAR-200 has shown to eliminate bladder cancer in 82% of patients in a clinical trial, especially effective for those unresponsive to traditional therapies, with the potential for FDA approval and improved quality of life for patients.